Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial

• DOI: 10.12688/wellcomeopenres.14007.1
• Publication Date: 2018-03-20T11:32:34Z
• Authors: Joseph Donovan; Nguyen Hoan Phu; Le Thi Phuong Thao; Nguyen Huu Lan; Nguyen Thi Hoang Mai; Nguyen Thi Mai Trang; Nguyen Thi Thu Hiep; Tran Bao Nhu; Bui Thi Bich Hanh; Vu Thi Phuong Mai; Nguyen Duc Bang; Do Chau Giang; Dang Thi Minh Ha; Jeremy Day; Nguyen TT Thuong; Nguyen Nang Vien; Ronald B. Geskus; Tran Tinh Hien; Evelyne Kestelyn; Marcel Wolbers; Nguyen Van Vinh Chau; Guy E. Thwaites
• Keywords: Tuberculous Meningitis

Tuberculosis kills more people than any other bacterial infection worldwide. In tuberculous meningitis (TBM), a common functional promoter variant (C/T transition) in the gene encoding leukotriene A4 hydrolase (LTA4H), predicts pre-treatment inflammatory phenotype and response to dexamethasone HIV-uninfected individuals. The primary aim of this study is determine whether LTA4H genotype determines benefit or harm from adjunctive Vietnamese adults with TBM. secondary investigate alternative management strategies individuals who develop drug induced liver injury (DILI) that will enable safe continuation rifampicin isoniazid therapy.